Nichi-Iko Takes Share Of Korean Biosimilar Firm, Gains Japanese Rights For Remicade And Herceptin Generics
This article was originally published in PharmAsia News
TOKYO - Nichi-Iko has upped its capability to bring biosimilars to the Japanese market, buying a 33 percent stake in South Korean biosimilar firm Aprogen, giving the Japanese generics maker exclusive rights to Aprogen products in Japan
You may also be interested in...
A joint venture with Korean conglomerate Samsung will be limited to making generic versions of non-Biogen products, although Samsung separately is working on a biosimilar of rituximab.
The $300 million Korean joint venture gives Samsung a global stage but raises questions about its Rituxan biosimilars program.
SINGAPORE - European drug maker Sanofi-Aventis is scouting for Asia-centric joint ventures or collaborative arrangements to accelerate its presence in the biosimilars space. Sanofi is hoping to make up ground as some of its global peers have advanced in the segment to capitalize on some of the biggest revenue drivers expected to unfold in the next five to eight years